Dr. Tripathy on Breast Cancer with Bone Metastases

Debu Tripathy, MD
Published: Saturday, Jul 16, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.
SELECTED
LANGUAGE
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x